Markets Trade Down In May…June Preview

I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a...

B Riley, Day One

Today was the first day of the B Riley Conference in Los Angeles at the Beverly Hilton, a hotel that has a 60's feel...

Harrow Comes Out of Allergan Lawsuit Unscathed

In late-breaking news on Thursday afternoon, a jury has ruled in the case of Allergan vs. Imprimis Pharmaceuticals. If you recall, Allergan had been...

Harrow Health Announces First Quarter 2019 Financial Results

SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2019. First Quarter 2019 and...

ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting

SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its participation...

Harrow Wins Another Battle In Legal Tussle With Allergan

This week Harrow won a partial summary judgement in their legal tussling with Allergan. This incremental positive supports the companies long-term business model and...

KKR’s Deal With Flying L Validates Harrow

It's always nice when some of the smartest people in the world tell you that what you're doing makes sense. In the case of...

BAUSCH HEALTH ACQUIRES ETON PHARMACEUTICALS’ EM-100 INVESTIGATIONAL EYE DROP FOR THE TREATMENT OF ITCHY...

Tailwinds' Take: this is a big deal for ETON, a company in which Harrow owns 3.5 million shares and has a royalty agreement. There...

Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations

Tailwinds' Take: we think MELT will end up bing a home run for Harrow, which is building a portfolio of solid companies. SAN DIEGO and...

Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual...

Tailwinds' Take: this acquisition positions Mayfield as the next subsidiary to be spun out from Harrow. The value of HROW keeps increasing with each...

What The MELT Financing Means To HROW

Today in a press release, Harrow announced the Series A financing of their (formerly) wholly owned subsidiary, Melt Pharmaceuticals. This is a very positive...

What To Put In Your Stockings: December Preview

This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least,...

Imprimis; Priming the Pumps for a Big 2019

If you've been paying attention to me, you know that I've been very bullish on Imprimis Pharmaceuticals (IMMY). In particular, my thinking was that...

Imprimis Pharmaceuticals Announces Third Quarter 2018 Results

SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the third quarter 2018. Third Quarter 2018 and...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and...

Tailwinds' Take: Melt is potentially the hidden gem in the Imprimis portfolio. I don't think the market equates any significant value to this subsidiary,...

Imprimis Primed For Big Rally

On Thursday evening, one of Tailwinds' readers, sensing a rally, asked me which stock in the TW universe had the following three characteristics: Down...

Imprimis Pharmaceuticals Announces Second Quarter 2018 Results

SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: ...

Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in...

SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through its ImprimisRx ophthalmology business today announced its Canadian partner, Advanced Dosage Forms Inc., will...

ImprimisRx’s Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract...

SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.